NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

CRISPR技術市場:2021年∼至2026年的預測

CRISPR Market - Forecasts from 2021 to 2026

出版商 Knowledge Sourcing Intelligence 商品編碼 1023210
出版日期 內容資訊 英文 112 Pages
商品交期: 最快1-2個工作天內
價格
CRISPR技術市場:2021年∼至2026年的預測 CRISPR Market - Forecasts from 2021 to 2026
出版日期: 2021年07月06日內容資訊: 英文 112 Pages
簡介

全球CRISPR技術的市場規模,2019年價值9億7,900萬美元,今後預計以35.96%的年複合成長率成長,預計2026年達到84億600萬美元的市場規模。

醫藥品研究的必要性的高漲,先天性異常的風險,晚孕引起生產時的問題等,是CRISPR技術市場發展的主要原因。還有老年人口增加,生活方式的變化,最尖端的研究技術的投資等市場規模也增大。遺傳性疾病逐漸一般化,對基因治療的人們的意識高漲,導致市場進一步發展。

本報告提供全球CRISPR技術市場調查,市場概要,市場成長要素及阻礙因素分析,市場機會,各類型,各地區的市場規模的變化與預測,競爭情形,主要企業簡介等資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 假設

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 新加入業者的威脅
    • 替代品的威脅
    • 產業的競爭企業間的敵對關係
  • 產業的價值鏈分析

第5章 各產品的CRISPR技術市場分析

  • 簡介
  • 設計工具
  • 質體和媒介
  • Cas9和g-RNA
  • 輸送系統產品

第6章 各應用領域的CRISPR技術市場分析

  • 簡介
  • 基因編輯
  • 基因工程學
  • GMO和作物
  • 人幹細胞
  • 其他

第7章 各地區的CRISPR技術市場分析

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 印尼
    • 台灣
    • 泰國
    • 其他

第8章 競爭資訊

  • 競爭基準與分析
  • 最近的投資和交易
  • 主要參與者的策略

第9章 企業簡介

  • Addgene
  • CRISPR Therapeutics
  • Editas Medicine
  • Egenesis, Inc.
  • GE Healthcare
  • GenScript Biotech Corporation
  • Horizon Discovery Group PLC
  • Integrated DNA Technologies, Inc.
  • Intellia Therapeutics, Inc.
  • Lonza Group
目錄
Product Code: KSI061610963

The global CRISPR market is evaluated at US$0.979 billion for the year 2019 and is estimated to grow at a CAGR of 35.96% to reach a market size of US$8.406 billion by the year 2026. The global CRISPR market is a growing with major investments from developed countries. The global genome editing market is witnessing a high growth rate after the discovery of a cutting-edge tool- "CRISPR", a shorthand for "Clustered Regularly Interspaced Short Palindromic Repeats". CRISPR-based tools are increasingly being adopted by enterprises globally for new developments in fields like genome editing, genetic engineering, biotechnology, pharmaceutical, and agriculture.

The growing need for drug research, the risk of congenital abnormalities, and late pregnancies resulting in birth problems are key factors driving the CRISPR market forward. The escalating geriatric population, Changes in lifestyles, and investment in cutting-edge research technologies are also augmenting the market size. Genetic illnesses are becoming more common, genetic diseases are becoming more prevalent, and people are becoming more aware of gene therapies leading to further development in the market.

Wide possible applications to drive the market growth.

CRISPR technology is widely utilized for a variety of applications. Genome editing, also known as genetic engineering, is a technique for altering an organism's genome by using molecular machinery and designed nucleases to make deletions, insertions, or substitutions in the DNA of a live creature. A gene library is a collection of cloned deoxyribonucleic acid (DNA) fragments that contain information on the functionality of a gene. CRISPR plasmids are widely utilized for gene disruption and homologous gene direct repair.

Pairwise, a CRISPR-focused food business, received USDA authorization in August 2020 for its gene-edited form of Brassica juncea, also known as mustard greens. Pairwise received word from the USDA that their innovative take on a leafy green that hasn't been on many menus owing to a strong odor and unpleasant taste has been authorized to continue ahead. Pairwise wants to produce a healthful and tasty alternative to kale and Brussels sprouts by using CRISPR technology to design modifications.

PerkinElmer and Qiagen are the recent medtechs to enter the fast-developing CRISPR industry, with technology meant to help gene editing to cure cancer, hemophilia, sickle cell anemia, and other illnesses. Qiagen has introduced new CRISPR products to help researchers better understand the gene-editing effect of their work, while PerkinElmer has acquired SIRION Biotech, a German viral vector gene delivery business, to expand its CRISPR gene editing toolkit in June 2021.

A rapid increase in genetic disorders to expand market demand.

The increase in genetic disorders is also facilitating the market demand. According to the Global Alliance for Genomics and Health (GA4GH), over 60 million individuals will have had their genome sequenced in a hospital setting by 2025, yet mechanisms for handling the data generated by genome sequencing are still in their infancy. As reported by US National Center for Biotechnology Information, even though genetic illnesses are individually rare, they constitute around 80% of rare disorders, which number in the thousands. The sheer quantity of uncommon illnesses implies that one out of every seventeen people is affected by it.

Capsida Biotherapeutics, a US-based startup, was formed in 2019 to employ gene therapy to treat severe illnesses. The firm just disclosed a significant development that might hasten its ambitions. The firm announced a collaboration with CRISPR Therapeutics, a pioneer in gene-based medicine, in June 2021 to co-develop therapies for two uncommon diseases with no known cures: Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS) and Friedreich's ataxia.

Escalating Research & Development to provide opportunities to the market players.

A lot of research and development happening in the market is anticipated to boost the opportunities through the inclining market trends. As reported by US National Cancer Institute, Since the discovery that mutations in DNA cause cancer, scientists have been looking for a simple approach to reverse such changes by altering DNA. Several techniques of gene editing have been developed over the years, but none have truly satisfied the criteria for a rapid, simple, and low-cost technology. Cancer researchers leaped at the possibility to utilise CRISPR as soon as it hit the shelves and freezers of labs throughout the world. CRISPR is now being tested on cancer patients rather than in lab dishes. Researchers tested a cancer treatment involving immune cells that were CRISPR-edited to better hunt down and attack cancer in a small study.

Insufficient awareness and the potential misuse to restrain the market growth.

The primary obstacles impeding the CRISPR market's growth are insufficient awareness and the potential misuse of CRISPR gene editing technologies. This technology faces a major challenge in developing nations such as those in the Asian and African regions, where potential consumers are ignorant of its extensive usage in several key research initiatives.

Geographically, North America is predicted to hold a significant market share of the global CRISPR market attributing to a thriving pharmaceutical and biotechnology industry, broad technology use, the growing frequency of lifestyle illnesses, rising healthcare costs, and increased R&D activities. The expanding biotechnology and pharmaceutical industries have also contributed to this rise. The CRISPR market in the area is seeing significant demand owing to the enormous applications in human stem cells and genetic engineering, as well as the expanding need for genetically modified organisms.

Market Segmentation:

  • By Products

Design Tools

Plasmid and Vector

Cas9 and g-RNA

Delivery System Products

  • By Applications

Genome Editing

Genetic Engineering

GMO and Crops

Human Stem Cells

Others

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • UK
  • Germany
  • France
  • Spain
  • Others

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Israel
  • Others

Asia Pacific

  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. CRISPR Market Analysis, By Products

  • 5.1. Introduction
  • 5.2. Design Tools
  • 5.3. Plasmid and Vector
  • 5.4. Cas9 and g-RNA
  • 5.5. Delivery System Products

6. CRISPR Market Analysis, By Application

  • 6.1. Introduction
  • 6.2. Genome Editing
  • 6.3. Genetic Engineering
  • 6.4. GMO and Crops
  • 6.5. Human Stem Cells
  • 6.6. Others

7. CRISPR Market Analysis, By Geography

  • 7.1. North America
    • 7.1.1. USA
    • 7.1.2. Canada
    • 7.1.3. Mexico
  • 7.2. South America
    • 7.2.1. Brazil
    • 7.2.2. Argentina
    • 7.2.3. Others
  • 7.3. Europe
    • 7.3.1. UK
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Spain
    • 7.3.5. Others
  • 7.4. Middle East and Africa
    • 7.4.1. Saudi Arabia
    • 7.4.2. Israel
    • 7.4.3. Others
  • 7.5. Asia Pacific
    • 7.5.1. Japan
    • 7.5.2. China
    • 7.5.3. India
    • 7.5.4. Indonesia
    • 7.5.5. Taiwan
    • 7.5.6. Thailand
    • 7.5.7. Others

8. Competitive Intelligence

  • 8.1. Competitive Benchmarking and Analysis
  • 8.2. Recent Investment and Deals
  • 8.3. Strategies of Key Players

9. Company Profiles

  • 9.1. Addgene
  • 9.2. CRISPR Therapeutics
  • 9.3. Editas Medicine
  • 9.4. Egenesis, Inc.
  • 9.5. GE Healthcare
  • 9.6. GenScript Biotech Corporation
  • 9.7. Horizon Discovery Group PLC
  • 9.8. Integrated DNA Technologies, Inc.
  • 9.9. Intellia Therapeutics, Inc.
  • 9.10. Lonza Group